EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines

Heiko Ilchmann, Nathaly Samy, Daniela Reichhardt, Darja Schmidt, Jacqueline D Powell, Thomas P H Meyer, Günter Silbernagl, Rick Nichols, Heinz Weidenthaler, Laurence De Moerlooze, Liddy Chen iD, Paul Chaplin

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiac455 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Heiko Ilchmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Harrison Clinical Research Deutschland, GmbH, Munich, Germany. Hauptthemen laut MEDLINE: Smallpox, Vaccinia, Smallpox Vaccine. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Bavarian Nordic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination is approved for smallpox and monkeypox prevention, immunological persistence and booster effects remain undescribed.

Methods

Participants naive to smallpox vaccination were randomized to 1 dose MVA-BN (1×MVA, n = 181), 2 doses MVA-BN (2×MVA, n = 183), or placebo (n = 181). Participants with previous smallpox vaccination received 1 MVA-BN booster (HSPX, n = 200). Subsets of the formerly naive groups (approximately 75 each) received an MVA-BN booster 2 years later.

Results

Neutralizing antibody (nAb) geometric mean titers (GMTs) increased from 1.1 (baseline, both naive groups) to 7.2 and 7.5 (week 4, 1×MVA and 2×MVA, respectively), and further to 45.6 (week 6, 2×MVA after second vaccination). In HSPX, nAb GMT rapidly increased from 21.6 (baseline) to 175.1 (week 2). At 2 years, GMTs for 1×MVA, 2×MVA, and HSPX were 1.1, 1.3, and 10.3, respectively. After boosting in the previously naive groups, nAb GMTs increased rapidly in 2 weeks to 80.7 (1×MVA) and 125.3 (2×MVA), higher than after primary vaccination and comparable to boosted HSPX subjects. Six months after boosting, GMTs were 25.6 (1×MVA) and 49.3 (2×MVA). No safety concerns were identified.

Conclusions

Anamnestic responses to boosting without sustained high nAb titers support presence of durable immunological memory following primary MVA-BN immunization. Clinical Trials Registration. NCT00316524 and NCT00686582.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SmallpoxVacciniaSmallpox VaccineHumansAntibodies, ViralVaccinia virusVaccinationAntibodies, Neutralizing

Stichwörter der Autor:innen

boostermemory responsemonkeypoxorthopoxvirusrecall responserevaccinationvaccinia experienced

Substanzen

Antibodies, ViralSmallpox VaccineAntibodies, Neutralizing

Autor:innen und Institutionen

  • Harrison Clinical Research Deutschland, GmbH, Munich, Germany.
  • Bavarian Nordic, GmbH, Martinsried, Germany.
  • Bavarian Nordic, Inc, Durham, North Carolina, USA.
  • Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.
  • Public Health Vaccines, LLC, Cambridge, Massachusetts, USA.
  • Bavarian Nordic, AG, Zug, Switzerland.

ORCID-Profile: Liddy Chen

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Bavarian Nordic

Zitieren

APA

Ilchmann, H., Samy, N., Reichhardt, D., Schmidt, D., Powell, J. D., Meyer, T. P. H., Silbernagl, G., Nichols, R., Weidenthaler, H., De Moerlooze, L., Chen, L., & Chaplin, P. (2023). One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac455

Vancouver

Ilchmann H, Samy N, Reichhardt D, Schmidt D, Powell JD, Meyer TPH, et al. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac455

BibTeX
@article{Ilchmann2023,
  author = {Ilchmann, Heiko and Samy, Nathaly and Reichhardt, Daniela and Schmidt, Darja and Powell, Jacqueline D and Meyer, Thomas P H and Silbernagl, Günter and Nichols, Rick and Weidenthaler, Heinz and De Moerlooze, Laurence and Chen, Liddy and Chaplin, Paul},
  title = {One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiac455}
}
Kostenlos starten →